T 1708/18 (PCSK9 variants/BRISTOL-MYERS SQUIBB) vom 14.02.2022
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2022:T170818.20220214
- Datum der Entscheidung
- 14. Februar 2022
- Aktenzeichen
- T 1708/18
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 07873840.8
- IPC-Klasse
- A61K 38/00C12N 9/64
- Verfahrenssprache
- Englisch
- Verteilung
- Nicht verteilt (D)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- Zusammenfassung von EPC2000 Art 117
- Bezeichnung der Anmeldung
- Polynucleotides encoding novel PCSK9 variants
- Name des Antragstellers
- Bristol-Myers Squibb Company
- Name des Einsprechenden
- Regeneron Pharmaceuticals, Inc.
Sanofi
Pfizer Inc. - Kammer
- 3.3.04
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 54
- Schlagwörter
- Novelty - (no)
- Orientierungssatz
- 1. The issue of which standard of disclosure applies when assessing the legal question of novelty and the issue of which standard of proof applies when assessing evidence and factual questions are distinct and unrelated. The fact that the standard of disclosure required for a finding of lack of novelty (or for allowing an amendment to the application under Article 123(2) EPC) is the standard of a direct and unambiguous disclosure is immaterial for the question of what standard of proof applies when considering evidence and factual issues in the context of novelty (or inventive step) (see point 16).
2. The standard of proof generally applied at the EPO for deciding on an issue of fact is the balance of probabilities. According to this standard, the EPO must base its decisions on statements of fact which, based on the available evidence, are more likely than not to be true. This standard also applies when examining factual issues in the context of novelty (see point 14). - Zitierende Akten
- T 0358/22
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is revoked.